Louisiana launches psychedelic therapy pilot funded by opioid settlement

Louisiana's new psychedelic therapy program, backed by opioid litigation funds, launches as state charts mixed cannabis policy course.

FILE — statehouse · B.D. Gilfry / CC BY-SA 2.0

Louisiana has activated a psychedelic therapy pilot program financed through opioid settlement funds, according to Marijuana Moment. The initiative represents a clinical pivot toward alternative treatments for conditions traditionally managed with opioids—a departure from Louisiana's broader cannabis stance over the past two months.

The timing reflects regulatory tension in the state. While the psychedelic program advances, Louisiana has simultaneously enacted stiffer cannabis penalties near campuses, blocked an adult-use pilot program, and pursued medical marijuana tax relief. The attorney general's withdrawal from federal rescheduling litigation suggests some official openness to cannabinoid science, yet enforcement actions—including a recent narcotics arrest in Calcasieu Parish—continue.

The psychedelic pilot's trajectory will signal whether Louisiana views non-cannabis plant medicines as a controlled path forward. Watch whether clinical outcomes from this program influence future cannabis policy or remain siloed as a separate regulatory category.